Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Strong analyst reports for Coca-Cola and others gave underlying support to a market buffeted once again by rising oil price concerns and Friday’s $250 million verdict against Merck & Co. Though the verdict in the case against the company’s Vioxx drug dampened enthusiasm, UBS revised its recommendation on Coca-Cola from “neutral” to “buy,” pushing the company’s stock up nearly 2 percent. The Dow finished the week relatively flat at 10,559.23, down 101.08 points (nearly 0.1
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in